US equities |
NVDA $233.95 ▲+1.34% MU $1,074.89 ▼-2.05% TSLA $370.59 ▲+4.65% SPCX $158.96 ▲+7.35% SNDK $1,719.99 ▼-3.79% AMD $633.91 ▲+2.95% STX $848.99 ▼-10.21% INTC $119.33 ▼-0.56%
FinancialContent

Johnson & Johnson (NY:JNJ)

256.03 -2.63 (-1.02%)
Official Closing Price Updated: 7:00 PM EDT, Oct 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Johnson & Johnson

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
News headline image
Every Few Decades, Aesthetics Gets a New Category. One Preclinical Company Thinks Its Extra Cellular Matrix Platform Could Create the Next One
Issued on behalf of Conexeu Sciences Inc. (Nasdaq: CNXU) 
From American News Group
Via GlobeNewswire
News headline image
Johnson & Johnson’s Executive Vice President Jennifer Taubert to Retire; Tom Cavanaugh Appointed EVP, Worldwide Chairman Innovative Medicine Effective September
From Johnson & Johnson
Via Business Wire
Explore the top gainers and losers within the dow jones index in today's session. ↗
Via Chartmill
Top dow jones movers in Monday's session ↗
Via Chartmill
News headline image
The S&P 493 Are Staging a Comeback—This Value ETF Offers Broad Exposure ↗
As the NASDAQ-100 corrects amid an AI CapEx-driven tech sell-off, sectors like healthcare and financials are rallying, boosting diversified value ETFs like the Schwab U.S. Large-Cap Value ETF (SCHV). 
Via MarketBeat
Topics Artificial Intelligence ETFs Stocks
News headline image
Johnson & Johnson’s OTTAVA Robotic Surgery System Targets Long-Term Growth ↗
Johnson & Johnson (NYSE:JNJ) outlined its commercialization plans for the OTTAVA robotic surgical system after receiving U.S. Food and Drug Administration De Novo authorization, positioning the... 
Via MarketBeat
Topics Artificial Intelligence ETFs
News headline image
3 Dividend Stocks That Are No-Brainer Buys for the Second Half of 2026 ↗
As stocks pull back from recent highs, lean into these three blue chip dividend stocks. 
Via The Motley Fool
News headline image
3 Dividend Stocks to Buy and Hold Forever ↗
They have a combined 181 years of consecutive payout increases. 
Via The Motley Fool
Topics Intellectual Property Lawsuit
News headline image
Abbott Laboratories vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026? ↗
Abbott trades at a cheaper valuation but carries higher litigation risk, while J&J boasts superior profitability despite a pending talc settlement. 
Via The Motley Fool
These dow jones stocks are moving in today's session ↗
Via Chartmill
News headline image
Johnson & Johnson Shares Edge Higher as $3.5B Biotech Moves Expand Oncology Pipeline ↗
Johnson & Johnson (NYSE: JNJ) shares are edging higher on Friday as investors digest two major biotech pipeline moves. 
Via Benzinga
News headline image
Johnson & Johnson Just Got FDA Clearance for Its Surgical Robot, Hiked Its Dividend for the 64th Time, and Is Targeting $100 Billion in Revenue. But Here's What Investors Should Be Most Excited About ↗
Things are going well for the pharmaceutical giant. 
Via The Motley Fool
Topics Lawsuit
Explore the top gainers and losers within the dow jones index in today's session. ↗
Via Chartmill
Which dow jones stocks are moving on Thursday? ↗
Via Chartmill
News headline image
Johnson & Johnson Advances Cancer and Immunology Treatments With Major Biotech Deals ↗
Johnson & Johnson expands its biotech pipeline with Firefly Bio acquisition and a strategic partnership with Sail Biomedicines. 
Via Benzinga
News headline image
Johnson & Johnson Completes Acquisition of Firefly Bio, Inc. to Advance Next-Generation Oncology Innovation
From Johnson & Johnson
Via Business Wire
News headline image
Johnson & Johnson Announces Collaboration with Sail Biomedicines to Advance in vivo CAR-T Programs and Transform Autoimmune Disease Through Immune Reset
From Johnson & Johnson
Via Business Wire
News headline image
Meet the Stock That's Obliterating Eli Lilly, Johnson & Johnson, and AbbVie Right Now ↗
But is that performance sustainable? 
Via The Motley Fool
Uncover the latest developments among dow jones stocks in today's session. ↗
Via Chartmill
News headline image
Johnson & Johnson vs. Eli Lilly: Reliable Stability vs. Rapid Revenue Growth ↗
Johnson & Johnson's revenue has grown modestly while Eli Lilly's revenue has nearly doubled in two years, narrowing a once-wide gap. 
Via The Motley Fool
Chips Sell First, Ask Questions Later - And SK Hynix Just Handed Them the Answer ↗
Via Chartmill
News headline image
Johnson & Johnson Puts 15-Year Meritless Talc Litigation To Rest ↗
Johnson & Johnson reached a $5.5 billion agreement to resolve remaining federal and state talc litigation over ovarian cancer claims. 
Via Benzinga
News headline image
Stock Market Today: Dow Jones Futures Gain, Nasdaq 100 Declines as Oil Slips Ahead of Trump's Meetings With Zelensky and Netanyahu—Boeing, Coca-Cola, Johnson & Johnson in Focus ↗
U.S. stock futures were mixed on Tuesday, as the Dow Jones index gained but the S&P 500 and Nasdaq 100 indices declined. 
Via Benzinga
Topics Government Stocks
News headline image
Johnson & Johnson Announces a Proposed Resolution of Ovarian Talc Litigation
From Johnson & Johnson
Via Business Wire
News headline image
If I Only Had $500 to Invest, This Is the ETF I'd Buy Right Now ↗
This value ETF offers a great value for investors right now. 
Via The Motley Fool
Topics ETFs Economy
News headline image
Better Dividend King to Buy Right Now: AbbVie or Johnson & Johnson? ↗
Both have very promising futures. 
Via The Motley Fool
Which dow jones stocks are moving on Friday? ↗
Via Chartmill
Explore the top gainers and losers within the dow jones index in today's session. ↗
Via Chartmill
News headline image
This "Boring" Dividend King Is Quietly Turning Into a Growth Machine -- and Many Investors Are Missing It ↗
A name that's often ignored by investors due to its limited historic growth is evolving into a solid income-growth prospect. 
Via The Motley Fool
Topics Intellectual Property
News headline image
2 Top Growth Stocks to Buy Right Now Without Any Hesitation ↗
There are plenty of reasons to love these companies. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >